143 related articles for article (PubMed ID: 35193807)
21. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis.
Nelson RA; Guye ML; Luu T; Lai LL
Ann Surg Oncol; 2015 Jan; 22(1):24-31. PubMed ID: 25012264
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009.
Cloyd JM; Hernandez-Boussard T; Wapnir IL
Ann Surg Oncol; 2013 May; 20(5):1545-50. PubMed ID: 23460016
[TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics and Prognosis of Metaplastic Breast Cancer Compared with Invasive Ductal Carcinoma: A Propensity-Matched Analysis.
Lee JH; Ryu JM; Lee SK; Chae BJ; Lee JE; Kim SW; Nam SJ; Yu J
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900347
[TBL] [Abstract][Full Text] [Related]
26. Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease.
Goel N; Yadegarynia S; Rodgers S; Kelly K; Collier A; Franceschi D; Moller M; Avisar E; Kesmodel SB
J Surg Oncol; 2021 Jul; 124(1):25-32. PubMed ID: 33852160
[TBL] [Abstract][Full Text] [Related]
27. Locoregional and Distant Outcomes in Women With cT1-3N1 Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Adjuvant Radiotherapy.
Kozak MM; von Eyben R; Gutkin PM; Vemuri M; Jacobson CE; Karl JJ; Walck E; Marquez C; Horst KC
Clin Breast Cancer; 2021 Aug; 21(4):373-382. PubMed ID: 33766533
[TBL] [Abstract][Full Text] [Related]
28. Comparison of outcomes between metaplastic and triple-negative breast cancer patients.
Polamraju P; Haque W; Cao K; Verma V; Schwartz M; Klimberg VS; Hatch S; Niravath P; Butler EB; Teh BS
Breast; 2020 Feb; 49():8-16. PubMed ID: 31675684
[TBL] [Abstract][Full Text] [Related]
29. Metaplastic carcinoma of the breast: matched cohort analysis of recurrence and survival.
Narayan P; Kostrzewa CE; Zhang Z; O'Brien DAR; Mueller BA; Cuaron JJ; Xu AJ; Bernstein MB; McCormick B; Powell SN; Khan AJ; Wen HY; Braunstein LZ
Breast Cancer Res Treat; 2023 Jun; 199(2):355-361. PubMed ID: 36976395
[TBL] [Abstract][Full Text] [Related]
30. Does treatment sequence affect outcomes in patients with metaplastic breast cancer?
Ladipo OL; Ren Y; Caddell KB; Sampathkumar A; Almond CA; Fayanju OM
Am J Surg; 2021 Apr; 221(4):701-705. PubMed ID: 33526302
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
[TBL] [Abstract][Full Text] [Related]
32. Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China.
Chen R; Li S; Li Y; Zhu Q; Shi X; Xu L; Xu Y; Zhang W; Huang X; Wang J; Zha X
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3495-3501. PubMed ID: 34398298
[TBL] [Abstract][Full Text] [Related]
33. Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database.
Ong CT; Campbell BM; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Force J; Hall A; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2018 Aug; 25(8):2249-2260. PubMed ID: 29855830
[TBL] [Abstract][Full Text] [Related]
34. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
[No Abstract] [Full Text] [Related]
35. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
36. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
37. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
[TBL] [Abstract][Full Text] [Related]
39. Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
Lai V; Hajjaj O; Le D; Shokoohi A; Chia S; Simmons C
Breast Cancer Res Treat; 2020 Dec; 184(3):755-762. PubMed ID: 33001336
[TBL] [Abstract][Full Text] [Related]
40. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
